

David A Pattison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2259527/publications.pdf>

Version: 2024-02-01

51
papers

2,036
citations

361413

20
h-index

254184

43
g-index

56
all docs

56
docs citations

56
times ranked

2062
citing authors

#	ARTICLE	IF	CITATIONS
1	[¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet</i> , The, 2021, 397, 797-804.	13.7	552
2	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865.	5.0	191
3	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689.	1.9	181
4	⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , 2016, 16, 22.	2.8	135
5	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3278-3287.	3.6	125
6	⁶⁴ Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 777-785.	5.0	98
7	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , 2019, 29, 1634-1645.	4.5	69
8	⁶⁸ Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 477-482.	6.4	54
9	Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. <i>Andrology</i> , 2013, 1, 583-589.	3.5	49
10	TheraP: ¹⁷⁷ Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5000-5000.	1.6	44
11	High clinical and morphologic response using ⁹⁰ Y-DOTA-octreotate sequenced with ¹⁷⁷ Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 476-489.	6.4	42
12	Clinical insignificance of [¹⁸ F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4495-4507.	6.4	41
13	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. <i>Endocrine-Related Cancer</i> , 2017, 24, R203-R221.	3.1	36
14	Prospective intra-individual blinded comparison of [¹⁸ F]PSMA-1007 and [⁶⁸ Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 763-776.	6.4	36
15	¹⁸ F-FDG—Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 749-755.	5.0	35
16	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021, 128, 331-342.	2.5	33
17	Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. <i>Nuclear Medicine Communications</i> , 2015, 36, 356-362.	1.1	27
18	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284.	5.0	25

#	ARTICLE	IF	CITATIONS
37	Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. <i>EJNMMI Research</i> , 2021, 11, 128.	2.5	6
38	Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. <i>Internal Medicine Journal</i> , 2018, 48, 97-98.	0.8	4
39	Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging. <i>Urology</i> , 2018, 114, e1-e2.	1.0	4
40	THYROPET Study: Is It Biology or Technology That Is the Issue?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 354.1-354.	5.0	3
41	Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. <i>Journal of Critical Care</i> , 2020, 60, 319-322.	2.2	3
42	[18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD. <i>Bone Marrow Transplantation</i> , 2022, 57, 517-519.	2.4	3
43	Exercise-associated hyponatraemia on the Kokoda Track. <i>Medical Journal of Australia</i> , 2011, 194, 247-248.	1.7	2
44	Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin. <i>American Journal of Hematology</i> , 2016, 91, 1167-1168.	4.1	2
45	Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI. <i>Clinical Nuclear Medicine</i> , 2021, 46, e448-e450.	1.3	2
46	All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. <i>European Urology Oncology</i> , 2022, 5, 283-284.	5.4	2
47	99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis. <i>Clinical Nuclear Medicine</i> , 2022, 47, e582-e584.	1.3	2
48	Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2018, 43, 186-187.	1.3	1
49	Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk Myocardium. <i>Circulation</i> , 2013, 128, 567-570.	1.6	0
50	Management of Distant Metastasis in Differentiated Thyroid Cancer. , 2018, , 121-140.		0
51	Targeted Molecular Imaging of Translocator Protein (TSPO) Using 18FGE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). <i>Blood</i> , 2018, 132, 3397-3397.	1.4	0